Scinopharm Taiwan Stock Fundamentals
| 1789 Stock | TWD 23.50 0.15 0.63% |
ScinoPharm Taiwan fundamentals help investors to digest information that contributes to ScinoPharm Taiwan's financial success or failures. It also enables traders to predict the movement of ScinoPharm Stock. The fundamental analysis module provides a way to measure ScinoPharm Taiwan's intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to ScinoPharm Taiwan stock.
ScinoPharm |
ScinoPharm Taiwan Company Current Valuation Analysis
ScinoPharm Taiwan's Enterprise Value is a firm valuation proxy that approximates the current market value of a company. It is typically used to determine the takeover or merger price of a firm. Unlike Market Cap, this measure takes into account the entire liquid asset, outstanding debt, and exotic equity instruments that the company has on its balance sheet. When a takeover occurs, the parent company will have to assume the target company's liabilities but will take possession of all cash and cash equivalents.
Current ScinoPharm Taiwan Current Valuation | 16.28 B |
Most of ScinoPharm Taiwan's fundamental indicators, such as Current Valuation, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, ScinoPharm Taiwan is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Enterprise Value can be a useful tool to compare companies with different capital structures. Long term liability and current cash or cash equivalents can have a huge impact on market valuation of a given company.
| Competition |
In accordance with the recently published financial statements, ScinoPharm Taiwan has a Current Valuation of 16.28 B. This is 13.34% higher than that of the Pharmaceuticals sector and 118.96% higher than that of the Health Care industry. The current valuation for all Taiwan stocks is 2.07% higher than that of the company.
ScinoPharm Taiwan Fundamental Drivers Relationships
Comparative valuation techniques use various fundamental indicators to help in determining ScinoPharm Taiwan's current stock value. Our valuation model uses many indicators to compare ScinoPharm Taiwan value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across ScinoPharm Taiwan competition to find correlations between indicators driving ScinoPharm Taiwan's intrinsic value. More Info.ScinoPharm Taiwan is rated fifth in return on equity category among its peers. It also is rated fifth in return on asset category among its peers reporting about 0.62 of Return On Asset per Return On Equity. The ratio of Return On Equity to Return On Asset for ScinoPharm Taiwan is roughly 1.60 . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the ScinoPharm Taiwan's earnings, one of the primary drivers of an investment's value.ScinoPharm Current Valuation Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses ScinoPharm Taiwan's direct or indirect competition against its Current Valuation to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of ScinoPharm Taiwan could also be used in its relative valuation, which is a method of valuing ScinoPharm Taiwan by comparing valuation metrics of similar companies.ScinoPharm Taiwan is currently under evaluation in current valuation category among its peers.
ScinoPharm Fundamentals
| Return On Equity | 0.0295 | |||
| Return On Asset | 0.0184 | |||
| Profit Margin | 0.10 % | |||
| Operating Margin | 0.12 % | |||
| Current Valuation | 16.28 B | |||
| Shares Outstanding | 790.74 M | |||
| Shares Owned By Insiders | 58.97 % | |||
| Shares Owned By Institutions | 16.86 % | |||
| Price To Earning | 51.64 X | |||
| Price To Book | 1.92 X | |||
| Price To Sales | 6.90 X | |||
| Revenue | 2.76 B | |||
| Gross Profit | 1.28 B | |||
| EBITDA | 690.37 M | |||
| Net Income | 243.47 M | |||
| Cash And Equivalents | 4.72 B | |||
| Cash Per Share | 5.97 X | |||
| Total Debt | 2.29 B | |||
| Debt To Equity | 21.10 % | |||
| Current Ratio | 3.38 X | |||
| Book Value Per Share | 13.15 X | |||
| Cash Flow From Operations | 509.82 M | |||
| Earnings Per Share | 0.39 X | |||
| Target Price | 27.0 | |||
| Number Of Employees | 47 | |||
| Beta | 0.42 | |||
| Market Capitalization | 20.44 B | |||
| Total Asset | 11.69 B | |||
| Retained Earnings | 1.05 B | |||
| Working Capital | 3.95 B | |||
| Current Asset | 6.2 B | |||
| Current Liabilities | 2.25 B | |||
| Z Score | 4.8 | |||
| Annual Yield | 0.02 % | |||
| Five Year Return | 1.22 % | |||
| Net Asset | 11.69 B | |||
| Last Dividend Paid | 0.48 |
About ScinoPharm Taiwan Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze ScinoPharm Taiwan's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of ScinoPharm Taiwan using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of ScinoPharm Taiwan based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.ScinoPharm Taiwan, Ltd., together with its subsidiaries, researches and develops, produces, and sells CGMP active pharmaceutical ingredients to pharmaceutical companies in Taiwan, the United States, Europe, India, rest of Asia, and internationally. ScinoPharm Taiwan, Ltd. was founded in 1997 and is headquartered in Tainan, Taiwan. SCINOPHARM TAIWAN operates under Drug Manufacturers - Specialty Generic classification in Taiwan and is traded on Taiwan Stock Exchange.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for ScinoPharm Stock Analysis
When running ScinoPharm Taiwan's price analysis, check to measure ScinoPharm Taiwan's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy ScinoPharm Taiwan is operating at the current time. Most of ScinoPharm Taiwan's value examination focuses on studying past and present price action to predict the probability of ScinoPharm Taiwan's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move ScinoPharm Taiwan's price. Additionally, you may evaluate how the addition of ScinoPharm Taiwan to your portfolios can decrease your overall portfolio volatility.